Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 16079-16094
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16079
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16079
Table 1 Studies conducted on animal models showing effects of probiotics containing Bifidobacterium strains on metabolic disorders
Studied animals | Probiotic | Dose | Duration of treatment (wk) | Effects | Ref. |
C57BL/6J mice | Bifidobacterium breve B-3 | 109 CFU | 8 | ↓body weight, epididymal fat, serum cholesterol, glucose, insulin and HOMA index | [99] |
↑expression of FIAF, adiponectin | |||||
C57BL-6 mice | Bifidobacterium pseudocatenulatum CECT 7765 | 7 | ↓serum cholesterol, triglycerides, glucose, insulin resistance, leptin, IL-6, monocyte chemotactic protein-1, liver steatosis, adipose tissue | [100] | |
↑glucose tolerance | |||||
Improvement of immune system functionality | |||||
HFD-fed rats | Bifidobacterium longum | Improvement of HFD induced metabolic disorders trough ↓endotoxin levels and intestinal inflammation, ↑expression of Reg I genes | [101] | ||
HFD-rats, standard diets fed rats | Bifidobacterium adolescentis | 12 | ↓visceral fat, liver steatosis | [102] | |
↑insulin sensitivity | |||||
Sprague-Dawley rats | B. pseudocatenulatum SPM 1204, B. longum SPM 1205, and B. longum SPM 1207 | 108-109 CFU | 7 | ↓body and fat weights, serum cholesterol, triglycerides, glucose, leptin, AST, ALT and lipase levels | [103] |
Sprague-Dawley rats | Bifidobacteria L66-5, L75-4, M13-4 and FS31-12, originated from normal human intestines | 108 CFU | 6 | B. M13-4 strain ↑body weight | [104] |
B. L66-5 strain ↓body weight | |||||
All strains ↓serum and liver triglycerides, serum and liver cholesterol |
Table 2 Studies conducted on animal models showing effects of probiotics containing Lactobacillus strains on metabolic disorders
Studied subjects | Probiotic | Duration of treatment | Effects | Ref. |
C57BL/6J mice | Lactobacillus rhamnosus PL60 | 8 wk | ↓body weight gain, white adipose tissue, hepatic steatosis | [106] |
C57BL/6J mice | Lactobacillus plantarum PL62 | 8 wk | ↓body weight, visceral adipose tissue, serum glucose levels | [107] |
Sprague-Dawley rats | Lactobacillus gasseri SBT2055 | 4 wk | ↓adipocyte size, leptin levels | [108] |
No significant changes in serum glucose and lipids levels, and liver lipids levels | ||||
Zucker diabetic fatty rats | Lactobacillus fermentum NCIMB 5221 | 8 wk | ↓fasting insulin levels, insulin resistance, serum triglycerides and LDL cholesterol levels, atherosclerosis | [109] |
↑HDL cholesterol levels | ||||
Male Kunming mice | L. plantarum CAI6, L. plantarum SC4 | 28 d | ↓serum total and LDL cholesterol levels, LDL/HDL cholesterol ratio, triglycerides levels, hepatic steatosis | [110] |
↑serum HDL cholesterol, hepatic anti-oxidant Nrf-2 mediated response | ||||
C57BL/6J mice | Lactobacillus rhamnosus GG | 13 wk | ↓liver and mesenteric adipose tissue, weight gain | [111] |
↑glucose tolerance, gluconeogenesis, fatty acids oxidation | ||||
Apoe-/- mice | Lactobacillus reuteri ATCC PTA 4659 (ATCC), DSM 17938 (DSM), L6798 | 12 wk | ↓body weight gain, insulin levels, hepatic steatosis | [112] |
↑fatty acids oxidation | ||||
C57BL/6 mice | Lactobacillus plantarum strain No. 14 | 11 wk | ↓adipocyte size, white adipose tissue, serum leptin and total cholesterol levels | [113] |
C57B/6J mice | Lactobacillus paracasei ssp paracasei F19 | 10 d | ↓body weight | [114] |
↑triglyceride load of the lipoprotein VLDL, angiopoietin-like 4 protein that ↓fatty storage | ||||
GF and NMF mice | Lactobacillus paracasei ssp paracasei F19 or Lactobacillus acidophilus NCFB 1748 | 10 d | ↑adipsin, adiponectin, fatty acids oxidation | [115] |
Improvement of efficacy of intestinal immunological barrier | ||||
↓resistine like β |
Table 3 Studies conducted on humans showing effects of probiotics on metabolic disorders
Studied subjects | Probiotics | Duration of treatment | Effects | Ref. |
Overweight humans | Lactobacillus gasseri SBT2055 | 12 wk | ↓body weight, visceral and subcutaneous fat area, BMI, waist and hip circumference | [116] |
↑serum adiponectin | ||||
Subjects with increased abdominal adiposity | Lactobacillus gasseri SBT2055 | 12 wk | ↓body weight, visceral fat area, BMI, waist and hip circumference, body fat mass | [117] |
Women affected by postmenopausal metabolic syndrome | Lactobacillus plantarum | 90 d | ↓serum glucose and homocysteine levels | [118] |
Table 4 Studies conducted on animal models showing effects of prebiotics on metabolic disorders
Studied subjects | Prebiotic | Duration of treatment | Effects | Ref. |
Wistar rats | OFS | 50 d | ↓Body weight, food intake, fat mass, serum triglycerides, ghrelin | [126] |
↑GLP-1 | ||||
Wistar rats | OFS | 6 wk | ↓Food intake, serum glucose and insulin | [127] |
↑GLP-1, glucose tolerance | ||||
HFD fed mice | OFS | 13 wk | ↑Bifidobacterium, glucose tolerance | [105] |
↓Pro-inflammatory cytokines, endotoxemia | ||||
C57B/6J mice | OFS | 4 wk | ↓LPS, hepatic inflammatory and oxidative stress markers, intestinal permeability | [128] |
↑GLP-2 | ||||
C57B/6J mice | OFS | 8 wk | ↓Firmicutes/Bacteroides ratio, fat mass, oxidative stress, low grade inflammation | [129] |
↑Glucose tolerance, GLP-1 and leptin sensitivity | ||||
C57B/6J mice | AX | 4 wk | ↑Bacteroides, Prevotella, Roseburia, Bifidobacterium spp | [130] |
Improvement of gut barrier function | ||||
↓Adipocyte size, fatty acids storage, body weight, serum cholesterol, insulin resistance, low grade inflammation | [131] | |||
Lean and obese JCR:LA.cp rats | Inulin-OFS | 10 wk | ↓Firmicutes, food intake | |
↑Bacteroides, Bifidobacterium, satiety hormones |
Table 5 Studies conducted on humans showing effects of prebiotics on metabolic disorders
Studied subject | Prebiotic | Duration of treatment | Effects | Ref. |
Healthy men and women | OFS | 2 wk | ↓Food and energy intake, hunger | [132] |
↑satiety | ||||
Healthy humans | GOS | 12 wk | Significant ↑Bifidobacterium | [133] |
Obese women | Inulin-type fructans | 3 mo | ↑Bifidobacterium and Faecalibacterium prausnitzii | [134] |
↓Circulating LPS, Bacteroides, Propionibacterium | ||||
Obese-dyslipidemic women | Yacon syrup (containing OFS) | 120 d | ↓Body weight, BMI, waist circumference, serum LDL cholesterol levels | [135] |
Overweight and obese adults | OFS | 12 wk | ↓Body weight, ghrelin, calories intake, serum glucose, insulin | [136] |
↑peptide YY |
- Citation: Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol 2014; 20(43): 16079-16094
- URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16079.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.16079